on NFL BIOSCIENCES (EPA:ALNFL)
NFL Biosciences: Publication of its 2024 annual financial report
NFL Biosciences, a biopharmaceutical company specializing in botanical medicines, announced the publication of its annual financial report for fiscal year 2024. This document includes the management report, the corporate governance report, the annual financial statements, and the auditors' reports. All of this information is now publicly available and has been filed with the Autorité des marchés financiers (AMF).
The French company, listed on Euronext Growth in Paris, continues to develop innovative solutions for the treatment of addictions, with products such as NFL-101 for smoking cessation and NFL-301 for reducing alcohol consumption.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NFL BIOSCIENCES news